DexCom, Inc. (DXCM): Price and Financial Metrics
DexCom, Inc. (DXCM)
Today's Latest Price: $350.81 USD
Updated Jan 27 3:41pm
Add DXCM to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 188 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
DXCM Stock Summary
- DXCM's current price/earnings ratio is 150.18, which is higher than 94.18% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for DXCM is currently 77.59, higher than 93.44% of US stocks with positive operating cash flow.
- Over the past twelve months, DXCM has reported earnings growth of -341.82%, putting it ahead of merely 5.72% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Dexcom Inc are ANSS, GLW, TTD, RMD, and KEYS.
- DXCM's SEC filings can be seen here. And to visit Dexcom Inc's official web site, go to www.dexcom.com.
DXCM Stock Price Chart Interactive Chart >
DXCM Price/Volume Stats
| Current price | $350.81 | 52-week high | $456.23 |
| Prev. close | $361.42 | 52-week low | $182.07 |
| Day low | $350.41 | Volume | 784,745 |
| Day high | $361.21 | Avg. volume | 972,994 |
| 50-day MA | $350.18 | Dividend yield | N/A |
| 200-day MA | $381.32 | Market Cap | 33.69B |
DexCom, Inc. (DXCM) Company Bio
DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.
DXCM Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $350.81 | $413.42 | 14% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dexcom Inc. To summarize, we found that Dexcom Inc ranked in the 54th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Dexcom Inc ended up being:
- The company's balance sheet shows it gets 95% of its capital from equity, and 5% of its capital from debt. Notably, its equity weight is greater than 71.01% of US equities in the Healthcare sector yielding a positive free cash flow.
- The company's compound free cash flow growth rate over the past 5.5 years comes in at 0.84%; that's greater than 88.35% of US stocks we're applying DCF forecasting to.
- The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately only 16.63% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 12% |
| 1% | 13% |
| 2% | 14% |
| 3% | 16% |
| 4% | 17% |
| 5% | 18% |
FONR, REGN, UNH, CMD, and FZMD can be thought of as valuation peers to DXCM, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...